Favipiravir (T-705) inhibits in vitro norovirus replication

Biochemical and Biophysical Research Communications

Volumn 424, Issue 4, 2012, Pages 777-780

  Rocha Pereira, J ^a   Jochmans, D ^b   Dallmeier, K ^b   Leyssen, P ^b   Nascimento, M S J ^a   Neyts, J ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral activity; Norovirus; RNA dependent RNA polymerase; T 705

Indexed keywords

FAVIPIRAVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; IN VITRO STUDY; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; RNA ISOLATION; RNA SYNTHESIS; VIRUS REPLICATION;

AMIDES; ANIMALS; CELL LINE; MICE; NOROVIRUS; PYRAZINES; RNA, VIRAL; VIRUS REPLICATION;

MURINE NOROVIRUS; NOROVIRUS; ORTHOMYXOVIRIDAE;

EID: 84864803576     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.034     Document Type: Article

References (23)

1. Glass R.I., Parashar U.D., Estes M.K. Norovirus gastroenteritis. N. Engl. J. Med. 2009, 361:1776-1785.
2. Koo H.L., Ajami N., Atmar R.L., DuPont H.L. Noroviruses: the leading cause of gastroenteritis worldwide. Discov Med 2010, 10:61-70.
3. Beersma M.F., Schutten M., Vennema H., Hartwig N.G., Mes T.H., Osterhaus A.D., van Doornum G.J., Koopmans M. Norovirus in a dutch tertiary care hospital (2002-2007): frequent nosocomial transmission and dominance of GIIb strains in young children. J. Hosp. Infect. 2009, 71:199-205.
4. Hansen S., Stamm-Balderjahn S., Zuschneid I., Behnke M., Ruden H., Vonberg R.P., Gastmeier P. Closure of medical departments during nosocomial outbreaks: data from a systematic analysis of the literature. J. Hosp. Infect. 2007, 65:348-353.
5. Koopmans M. Progress in understanding norovirus epidemiology. Curr. Opin. Infect. Dis. 2008, 21:544-552.
6. Sukhrie F.H., Siebenga J.J., Beersma M.F., Koopmans M. Chronic shedders as reservoir for nosocomial transmission of norovirus. J. Clin. Microbiol. 2010, 48:4303-4305.
7. Green K.Y. Caliciviridae: the noroviruses. Fields virology 2007, 949-979. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
8. Zheng D.P., Ando T., Fankhauser R.L., Beard R.S., Glass R.I., Monroe S.S. Norovirus classification and proposed strain nomenclature. Virology 2006, 346:312-323.
9. Chang K.O., Sosnovtsev S.V., Belliot G., King A.D., Green K.Y. Stable expression of a norwalk virus RNA replicon in a human hepatoma cell line. Virology 2006, 353:463-473.
10. Wobus C.E., Karst S.M., Thackray L.B., Chang K.O., Sosnovtsev S.V., Belliot G., Krug A., Mackenzie J.M., Green K.Y., Virgin H.W. Replication of norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2004, 2:e432.
11. Wobus C.E., Thackray L.B., Virgin H.W. Murine norovirus: a model system to study norovirus biology and pathogenesis. J. Virol. 2006, 80:5104-5112.
12. Karst S.M., Wobus C.E., Lay M., Davidson J., Virgin H.W.t. STAT1-dependent innate immunity to a norwalk-like virus. Science 2003, 299:1575-1578.
13. Mumphrey S.M., Changotra H., Moore T.N., Heimann-Nichols E.R., Wobus C.E., Reilly M.J., Moghadamfalahi M., Shukla D., Karst S.M. Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. J. Virol. 2007, 81:3251-3263.
14. Hardy M.E. Norovirus protein structure and function. FEMS Microbiol. Lett. 2005, 253:1-8.
15. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., Watanabe Y., Narita H., Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 2002, 46:977-981.
16. Sidwell R.W., Barnard D.L., Day C.W., Smee D.F., Bailey K.W., Wong M.H., Morrey J.D., Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 2007, 51:845-851.
17. Gowen B.B., Smee D.F., Wong M.H., Hall J.O., Jung K.H., Bailey K.W., Stevens J.R., Furuta Y., Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008, 3:e3725.
18. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mendenhall M., Bailey K.W., Furuta Y., Sidwell R.W. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 2007, 51:3168-3176.
19. Julander J.G., Shafer K., Smee D.F., Morrey J.D., Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 2009, 53:202-209.
20. Morrey J.D., Taro B.S., Siddharthan V., Wang H., Smee D.F., Christensen A.J., Furuta Y. Efficacy of orally administered T-705 pyrazine analog on lethal west nile virus infection in rodents. Antiviral Res. 2008, 80:377-379.
21. Furuta Y., Takahashi K., Shiraki K., Sakamoto K., Smee D.F., Barnard D.L., Gowen B.B., Julander J.G., Morrey J.D. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009, 82:95-102.
22. Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H., Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005, 49:981-986.
23. Baert L., Wobus C.E., Van Coillie E., Thackray L.B., Debevere J., Uyttendaele M. Detection of murine norovirus 1 by using plaque assay, transfection assay, and real-time reverse transcription-PCR before and after heat exposure. Appl. Environ. Microbiol. 2008, 74:543-546.